Enfuvirtide
FDA approved · RxHIV fusion inhibitor peptide
Also known as: Fuzeon, T-20, Pentafuside, DP178, DP-178, Enfuvirtida, Fuzeon T-20, peptide T20
Strong, human-grade evidence
- Regulatory standing. FDA-approved prescription medicine
- Human trials. Backed by controlled human studies
- Registered human trials. 54 registered studies on ClinicalTrials.gov, most advanced Phase 4
- 1 cited source. Includes primary / regulatory sources
Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.
What it is
Enfuvirtide, also known as T-20 and sold as Fuzeon, is a synthetic 36 amino acid peptide derived from a region of the HIV-1 gp41 envelope protein. It is thought to act by binding gp41 and blocking the structural change the virus needs to fuse with and enter human immune cells.
What the evidence shows
Enfuvirtide is approved for the treatment of HIV-1 infection in combination with other antiretroviral drugs, mainly in treatment-experienced patients. Its antiviral effect is supported by registered human trials up to Phase 4 and a large published literature, though the public FDA database check used here did not confirm the approval record directly.
Key facts
Registered human trials
Live from ClinicalTrials.gov, refreshed daily.
Prospective Evaluation Among Patients Infected by HIV 1 in Virological Failure Owing to Lack of Compliance, of the Benefit in Terms of Compliance of an Optimised Antiretroviral Treatment With Enfuvirtide (Fuzeon) Associated With Two Active Molecules
A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
A Study of T-20 in HIV-Positive Adults
Published literature
Live from Europe PMC. This is how much has been published, not how much is proven in humans.
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Antiviral drugs in current clinical use.
Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Sources
- PubChem compound record (CID 16130199)
- Registered trials on ClinicalTrials.gov
- Published papers on Europe PMC
Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.